PROSTATE PSA: New US best practice guide for testing/treatment just posted

The American Urological Association’s newly revised PSA best practice guidelines have just been posted on the association’s website and there are a couple of significant changes.

Read Full Post »

PROSTATE TREATMENT: Two new studies look at mortality rates

Two studies presented at the American Urological Association annual meeting on Monday dealt with the mortality rates of men diagnosed with prostate cancer and treated with differing types of first line therapy.

Read Full Post »

PROSTATE TREATMENT: US/European patient lobbies call for vast improvements

Vast improvements in prostate cancer recognition, management and treatment are needed, according to influential prostate cancer groups, speaking at the American Urological Association annual meeting.

Read Full Post »

PROSTATE SCREENING: NZ government will review latest overseas studies

PROSTABLOG NZ (April 30): The Ministry of Health says it will be reviewing the two big, long-term trials in Europe and the US that looked at the effectiveness of prostate testing and screening over about a decade.

Read Full Post »

ROW 4 PROSTATE: Kiwis slipping off the pace while the women go for it

PROSTABLOG NZ (April 30): The prostates are fading, while the team rowing for breast cancer research is holding a close second in the Indian Ocean Rowing Race.

Read Full Post »

PROSTATE DRUG: Latest trial data on Provenge stacks up

Provenge boosted survival by 4.1 months, a result unlikely due to chance, says this background feature in Forbes Magazine that looks at the latest trial of the promising prostate cancer drug.

Read Full Post »

PROSTATE SCREENING: What should New Zealand do now?

The Americans have moved closer to the idea of national screening for prostate cancer, with a leading body recommending PSA tests for men aged 40.

Read Full Post »

PROSTATE DRUG: Provenge lowers risk of death 22.5%, say much-awaited study data

Dendreon’s immune-stimulating therapy for prostate cancer, called Provenge, was able to improve median survival time by 4.1 months, and lowered the risk of death by 22.5 percent.

Read Full Post »

PROSTATE RESEARCH: Testosterone inhibitor cuts risk of prostate cancer

GlaxoSmithKline PLC’s Avodart – dual 5-alpha-reductase inhibitor dutasteride which inhibits the conversion of testosterone into dihydrotesterone – cuts the risk of prostate cancer (and the same drug is also used to slow hair loss).

Read Full Post »

PROSTATE RESEARCH: Drug used for enlarged prostate also reduces cancer risk

Dutasteride (Avodart), a commonly prescribed drug to treat benign prostatic hyperplasia, has been shown to lower the risk of prostate cancer by 23 percent in men with an increased risk of the disease.

Read Full Post »